REPORT FROM THE ENS 2008 – Laquinimod, a novel immunomodulatory agent in clinical development, significantly reduces the number of gadolinium-enhancing lesions on MRI, according to the results of a phase II extension study (Comi et al. Abstract 0193. J Neurol 2008;255(suppl 2): 46).